Protection from clostridium difficile infection in CD4 T cell- and polymeric immunoglobulin receptor-deficient mice

Infection and Immunity

Volumn 82, Issue 2, 2014, Pages 522-531

  Johnston, Pehga F ^a   Gerding, Dale N ^a,b   Knight, Katherine L ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEUTRALIZING ANTIBODY; SECRETORY COMPONENT; TOXIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL IMMUNITY; BACTERIAL STRAIN; C57BL 6 MOUSE; CD4+ T LYMPHOCYTE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; EPITHELIUM; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; MOUSE; MUCOSA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM;

ANIMALS; ANTIBODIES, BACTERIAL; CD4-POSITIVE T-LYMPHOCYTES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, POLYMERIC IMMUNOGLOBULIN;

EID: 84893014123     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01273-13     Document Type: Article

References (41)

1. Rupnik M, Wilcox MH, Gerding DN. 2009. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7:526-536. http://dx.doi.org/10.1038/nrmicro2164.
2. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control Hosp. Epidemiol. 31:431-455. http://dx.doi.org /10.1086/651706.
3. Voth DE, Ballard JD. 2005. Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 18:247-263. http://dx.doi .org/10.1128/CMR.18.2.247-263.2005.
4. Savidge TC, Pan WH, Newman P, O'Brien M, Anton PM, Pothoulakis C. 2003. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 125:413-420. http://dx.doi.org/10 .1016/S0016-5085(03)00902-8.
5. Kelly CP. 2008. Clostridium difficile-more difficult than ever. N. Engl. J. Med. 359:1932-1940. http://dx.doi.org/10.1056/NEJMra0707500.
6. Khoruts A, Sadowsky MJ. 2011. Therapeutic transplantation of the distal gut microbiota. Mucosal Immunol. 4:4-7. http://dx.doi.org/10.1038/mi .2010.79.
7. Kyne L, Warny M, Qamar A, Kelly CP. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342:390-397. http://dx.doi.org/10.1056/NEJM2000021 03420604.
8. Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, Ambrosino D, Molrine D. 2010. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28:965-969. http://dx.doi.org/10 .1016/j.vaccine.2009.10.144.
9. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, Stack AM, Lowy I, Graziano R, Molrine D, Ambrosino DM, Thomas WD, Jr. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 74:6339-6347. http://dx.doi.org/10.1128/IAI .00982-06.
10. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD, Jr, Leney M, Sloan S, Hay CA, Ambrosino DM. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362:197-205. http://dx.doi.org/10.1056/NEJMoa 0907635.
11. Torres JF, Lyerly DM, Hill JE, Monath TP. 1995. Evaluation of formalininactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect. Immun. 63:4619- 4627.
12. Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, Giannasca PJ, Lee CK, Warny M, Monath TP, Kelly CP. 2005. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128:764-770. http://dx.doi.org/10.1053/j.gastro .2004.11.004.
13. Aboudola S, Kotloff KL, Kyne L, Warny M, Kelly EC, Sougioultzis S, Giannasca PJ, Monath TP, Kelly CP. 2003. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect. Immun. 71:1608-1610. http://dx.doi.org/10.1128/IAI.71.3.1608-1610.2003.
14. Siddiqui F, O'Connor JR, Nagaro K, Cheknis A, Sambol SP, Vedantam G, Gerding DN, Johnson S. 2012. Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive Clostridium difficile but does not prevent colonization. J. Infect. Dis. 205:128-133. http://dx.doi.org/10.1093/infdis/jir688.
15. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. 2008. A mouse model of Clostridium difficileassociated disease. Gastroenterology 135:1984-1992. http://dx.doi.org/10 .1053/j.gastro.2008.09.002.
16. Wilson KH, Kennedy MJ, Fekety FR. 1982. Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. J. Clin. Microbiol. 15:443-446.
17. Ghose C, Kalsy A, Sheikh A, Rollenhagen J, John M, Young J, Rollins SM, Qadri F, Calderwood SB, Kelly CP, Ryan ET. 2007. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infect. Immun. 75:2826 -2832. http://dx.doi.org/10 .1128/IAI.00127-07.
18. Macpherson AJ, Gatto D, Sainsbury E, Harriman GR, Hengartner H, Zinkernagel RM. 2000. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science 288: 2222-2226. http://dx.doi.org/10.1126/science.288.5474.2222.
19. Kaminski DA, Stavnezer J. 2006. Enhanced IgA class switching in marginal zone and B1 B cells relative to follicular/B2 B cells. J. Immunol. 177:6025-6029.
20. Lawley TD, Clare S, Walker AW, Goulding D, Stabler RA, Croucher N, Mastroeni P, Scott P, Raisen C, Mottram L, Fairweather NF, Wren BW, Parkhill J, Dougan G. 2009. Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect. Immun. 77: 3661-3669. http://dx.doi.org/10.1128/IAI.00558-09.
21. Ubeda C, Lipuma L, Gobourne A, Viale A, Leiner I, Equinda M, Khanin R, Pamer EG. 2012. Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLRdeficient mice. J. Exp. Med. 209:1445-1456. http://dx.doi.org/10.1084 /jem.20120504.
22. Johnson S, Gerding DN, Janoff EN. 1992. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J. Infect. Dis. 166:1287-1294. http://dx.doi.org/10.1093 /infdis/166.6.1287.
23. Johnson S, Sypura WD, Gerding DN, Ewing SL, Janoff EN. 1995. Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease. Infect. Immun. 63:3166-3173.
24. Katchar K, Taylor CP, Tummala S, Chen X, Sheikh J, Kelly CP. 2007. Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease. Clin. Gastroenterol. Hepatol. 5:707-713. http://dx.doi.org/10.1016/j.cgh.2007.02.025.
25. Kelly CP, Pothoulakis C, Orellana J, LaMont JT. 1992. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology 102:35-40.
26. Kyne L, Warny M, Qamar A, Kelly CP. 2001. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357:189-193. http://dx.doi.org/10.1016 /S0140-6736(00)03592-3.
27. Sun X, Wang H, Zhang Y, Chen K, Davis B, Feng H. 2011. Mouse relapse model of Clostridium difficile infection. Infect. Immun. 79:2856- 2864. http://dx.doi.org/10.1128/IAI.01336-10.
28. Sanchez TH, Brooks JT, Sullivan PS, Juhasz M, Mintz E, Dworkin MS, Jones JL. 2005. Bacterial diarrhea in persons with HIV infection, United States, 1992-2002. Clin. Infect. Dis. 41:1621-1627. http://dx.doi.org/10 .1086/498027.
29. Pulvirenti JJ, Gerding DN, Nathan C, Hafiz I, Mehra T, Marsh D, Kocka F, Rice T, Fischer SA, Segreti J, Weinstein RA. 2002. Difference in the incidence of Clostridium difficile among patients infected with human immunodeficiency virus admitted to a public hospital and a private hospital. Infect. Control Hosp. Epidemiol. 23:641-647. http://dx.doi.org /10.1086/501987.
30. Mody LR, Smith SM, Dever LL. 2001. Clostridium difficile-associated diarrhea in a VA medical center: clustering of cases, association with antibiotic usage, and impact on HIV-infected patients. Infect. Control Hosp. Epidemiol. 22:42-45. http://dx.doi.org/10.1086/501825.
31. Franco MA, Greenberg HB. 1997. Immunity to rotavirus in T cell deficient mice. Virology 238:169-179. http://dx.doi.org/10.1006/viro.1997 .8843.
32. Sha Z, Compans RW. 2000. Induction of CD4(+) T-cell-independent immunoglobulin responses by inactivated influenza virus. J. Virol. 74: 4999-5005. http://dx.doi.org/10.1128/JVI.74.11.4999-5005.2000.
33. Yao Q, Zhang R, Guo L, Li M, Chen C. 2004. Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine. J. Immunol. 173:1951-1958.
34. Kaetzel CS, Robinson JK, Chintalacharuvu KR, Vaerman JP, Lamm ME. 1991. The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA. Proc. Natl. Acad. Sci. U. S. A. 88:8796- 8800. http://dx.doi.org/10.1073/pnas.88.19.8796.
35. Robinson JK, Blanchard TG, Levine AD, Emancipator SN, Lamm ME. 2001. A mucosal IgA-mediated excretory immune system in vivo. J. Immunol. 166:3688-3692.
36. Fernandez MI, Pedron T, Tournebize R, Olivo-Marin JC, Sansonetti PJ, Phalipon A. 2003. Anti-inflammatory role for intracellular dimeric immunoglobulin A by neutralization of lipopolysaccharide in epithelial cells. Immunity 18:739-749. http://dx.doi.org/10.1016/S1074-7613(03)00122-5.
37. Corthesy B, Benureau Y, Perrier C, Fourgeux C, Parez N, Greenberg H, Schwartz-Cornil I. 2006. Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. J. Virol. 80:10692-10699. http://dx.doi.org/10.1128 /JVI.00927-06.
38. Mantis NJ, Rol N, Corthesy B. 2011. Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol. 4:603- 611. http://dx.doi.org/10.1038/mi.2011.41.
39. Steele J, Chen K, Sun X, Zhang Y, Wang H, Tzipori S, Feng H. 2012. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J. Infect. Dis. 205:384- 391. http://dx.doi.org/10.1093/infdis/jir748.
40. Brun P, Scarpa M, Grillo A, Palu G, Mengoli C, Zecconi A, Spigaglia P, Mastrantonio P, Castagliuolo I. 2008. Clostridium difficile TxAC314 and SLP-36kDa enhance the immune response toward a coadministered antigen. J. Med. Microbiol. 57:725-731. http://dx.doi .org/10.1099/jmm.0.47736-0.
41. Phillips JO, Russell MW, Brown TA, Mestecky J. 1984. Selective hepatobiliary transport of human polymeric IgA in mice. Mol. Immunol. 21: 907-914. http://dx.doi.org/10.1016/0161-5890(84)90147-0.